High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: results of a Spanish multicentre observational study.

IF 2.2 4区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY
Laura Andrés, Marisa Iborra, Raquel Vicente, Lara Arias, Pilar Nos, Ana Royo-Esteban, Beatriz Sicilia
{"title":"High persistence rate at one year- follow-up of subcutaneous vedolizumab at standard dose after switching endovenous vedolizumab, even in those previously intensified: results of a Spanish multicentre observational study.","authors":"Laura Andrés, Marisa Iborra, Raquel Vicente, Lara Arias, Pilar Nos, Ana Royo-Esteban, Beatriz Sicilia","doi":"10.1016/j.gastrohep.2025.502379","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Subcutaneous (sc) vedolizumab is an alternative to intravenous (iv) vedolizumab for the treatment of patients with mild-to-moderate flares of inflammatory bowel disease (IBD).</p><p><strong>Aims: </strong>To analyse the persistence rate of the sc vedolizumab and its pharmacokinetics in patients previously treated with iv vedolizumab; describing clinical and biochemical remission rates at one year, and comparing previous intravenous intensification regimens.</p><p><strong>Methods: </strong>Multicenter, descriptive, observational, and retrospective study of a cohort of 54 patients with IBD treated with iv vedolizumab for more than six months, who were switched to sc vedolizumab under a standard regimen, 32 patients (59%) with a diagnosis of ulcerative colitis (UC) and 22 patients (41%) with Crohn's disease (CD) RESULTS: After one year of follow-up, 93% of the patients continued with vedolizumab, 100% were in clinical remission, and 86% achieved biochemical remission (calprotectin <150). A progressive increase in vedolizumab levels was observed after switching to sc vedolizumab, with statistical significance (p<0.05). 14 patients (25.9%) were on an intensified regimen before switching to sc vedolizumab; however, all patients remained on subcutaneous vedolizumab at a dose of 108 mg every two weeks without the need for intensification.</p><p><strong>Conclusion: </strong>After switching to sc vedolizumab in patients with endovenous vedolizumab treatment, high persistence rate at one year of follow-up is achieved, with a greater tendency to biochemical remission, which is more pronounced in previously intensified patients without the need for subcutaneous vedolizumab intensification.</p>","PeriodicalId":12802,"journal":{"name":"Gastroenterologia y hepatologia","volume":" ","pages":"502379"},"PeriodicalIF":2.2000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterologia y hepatologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.gastrohep.2025.502379","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Subcutaneous (sc) vedolizumab is an alternative to intravenous (iv) vedolizumab for the treatment of patients with mild-to-moderate flares of inflammatory bowel disease (IBD).

Aims: To analyse the persistence rate of the sc vedolizumab and its pharmacokinetics in patients previously treated with iv vedolizumab; describing clinical and biochemical remission rates at one year, and comparing previous intravenous intensification regimens.

Methods: Multicenter, descriptive, observational, and retrospective study of a cohort of 54 patients with IBD treated with iv vedolizumab for more than six months, who were switched to sc vedolizumab under a standard regimen, 32 patients (59%) with a diagnosis of ulcerative colitis (UC) and 22 patients (41%) with Crohn's disease (CD) RESULTS: After one year of follow-up, 93% of the patients continued with vedolizumab, 100% were in clinical remission, and 86% achieved biochemical remission (calprotectin <150). A progressive increase in vedolizumab levels was observed after switching to sc vedolizumab, with statistical significance (p<0.05). 14 patients (25.9%) were on an intensified regimen before switching to sc vedolizumab; however, all patients remained on subcutaneous vedolizumab at a dose of 108 mg every two weeks without the need for intensification.

Conclusion: After switching to sc vedolizumab in patients with endovenous vedolizumab treatment, high persistence rate at one year of follow-up is achieved, with a greater tendency to biochemical remission, which is more pronounced in previously intensified patients without the need for subcutaneous vedolizumab intensification.

一项西班牙多中心观察性研究的结果:在转换静脉内维多单抗后,标准剂量皮下维多单抗的持续率高,即使在先前强化的患者中也是如此。
简介:皮下(sc) vedolizumab是静脉注射(iv) vedolizumab治疗轻度至中度炎症性肠病(IBD)患者的替代方案。目的:分析既往静脉注射维多珠单抗患者的sc维多珠单抗持续率及其药代动力学;描述临床和生化缓解率在一年内,并比较以往的静脉强化方案。方法:对54例IBD患者进行多中心、描述性、观察性和回顾性研究,这些患者接受静脉注射维多单抗治疗超过6个月,在标准方案下转为静脉注射维多单抗,32例(59%)诊断为溃疡性结肠炎(UC), 22例(41%)诊断为克罗恩病(CD)。随访1年后,93%的患者继续使用维多单抗,100%临床缓解,86%达到生化缓解(钙保护蛋白< 150)。改用sc维多单抗后,vedolizumab水平渐进式升高,差异有统计学意义(p < 0.05)。14名患者(25.9%)在改用维多单抗前接受强化治疗。然而,所有患者仍在皮下使用vedolizumab,每两周108 mg的剂量,不需要强化。结论:静脉内维多珠单抗治疗的患者改用sc维多珠单抗后,1年随访时的持续率较高,生化缓解的倾向更大,这在先前强化而不需要皮下维多珠单抗强化的患者中更为明显。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gastroenterologia y hepatologia
Gastroenterologia y hepatologia GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
1.50
自引率
10.50%
发文量
147
审稿时长
48 days
期刊介绍: Gastroenterology and Hepatology is the first journal to cover the latest advances in pathology of the gastrointestinal tract, liver, pancreas, and bile ducts, making it an indispensable tool for gastroenterologists, hepatologists, internists and general practitioners.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信